医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Micro Blood Science Inc.: Announcement of Developing the Next Generation Blood Test System Which Integrates the High Accuracy Finger Prick Blood Test Technology into Blockchain

2018年01月30日 PM02:09
このエントリーをはてなブックマークに追加


 

TOKYO

Micro Blood Science Inc. (hereinafter MBS), a Japanese blood testing device firm, today announces its plan to develop the next-generation blood test data management system which will securely store the blood test data derived from its proprietary finger prick blood test system, Lifee, thereby allowing the data to be used in a wide variety of medical and healthcare-related services.

MBS not only aims to create the worldwide healthcare eco system based on its innovative blood test services but also to increase the value of the test data information managed by the service users themselves.

In constructing this blood test results data platform, MBS seeks funding domestically and internationally through ICO. The white paper and the further details of the ICO such as the specifications of the tokens for sale and the timeframe of the transactions will become available on our information website in coming days.

About Micro Blood Science Inc.
Established in June 2006 and based in Tokyo, MBS manufactures microliter-scale blood sampling devices and operates the Lifee personal health record system. It also operates the MBS Laboratory model compact lab, which conducts commercial sample analysis using specialized high-level testing and ICT technology, and functions as the hub of the Lifee service.

View source version on businesswire.com: http://www.businesswire.com/news/home/20180129006288/en/

CONTACT

Micro Blood Science Inc.
Kei Ohtake or Minori Sameshima,
+81-3-6240-9200
mbs_ico@microbs.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用
  • 宝洁公司收购德国达姆施塔特默克集团的消费者健康业务
  • MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
  • Vaxart Announces $5 Million Inavir® Revenue Milestone
  • 和铂医药与科伦博泰开展全球合作,共同开发多个创新全人源抗体药物